Immuno-Biological Laboratories Co., Ltd. (4570) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Immuno-Biological Laboratories Co., Ltd. (4570:JPX), powered by AI.

Current Price
¥945
P/E Ratio
35.3
Market Cap
8.8B
Sector
Healthcare
What is the Immuno-Biological Laboratories Co., Ltd. stock price forecast?

Immuno-Biological Laboratories Co., Ltd. is currently trading at ¥945. View real-time AI analysis on Alpha Lenz.

What is Immuno-Biological Laboratories Co., Ltd. insider trading activity?

View the latest insider trading data for Immuno-Biological Laboratories Co., Ltd. on Alpha Lenz.

What is Immuno-Biological Laboratories Co., Ltd.'s P/E ratio?

Immuno-Biological Laboratories Co., Ltd.'s P/E ratio is 35.3.

Immuno-Biological Laboratories Co., Ltd.

JPX · 4570
¥945+28(+3.05%)Market closedJPX regular session 09:00–15:00 JST
Ask about Immuno-Biological Laboratories Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Immuno-Biological Laboratories Co., Ltd. trades at a P/E of 35.3 (premium valuation) with strong ROE of 17.9%. 3Y revenue CAGR of 14.4% highlights clear growth momentum.

Ask for details

Company Overview

Immuno-Biological Laboratories Co., Ltd. is a biotechnology company specializing in the research, development, and sale of diagnostic reagents and devices. The primary function of the company is to produce and supply cutting-edge immunological products used in clinical testing and life sciences research. Its offerings include various enzyme-linked immunosorbent assay (ELISA) kits, monoclonal and polyclonal antibodies, and other biochemical tools that play a crucial role in detecting and quantifying proteins, hormones, and other biomolecules. These products are pivotal for hospitals, laboratories, and research institutions in sectors such as healthcare, pharmaceuticals, and academic research. Immuno-Biological Laboratories Co., Ltd. is recognized for its contributions to advancing diagnostic capabilities and enhancing biomedical research methodologies. Its presence in the market underscores the increasing global demand for reliable and efficient diagnostic testing solutions, reflecting the expanding scope of personalized medicine and preventative healthcare measures.

SectorHealthcare
IndustryBiotechnology
Employees58

Company Statistics

FY 2025

Profile

¥8,801,217,810Market Cap
¥969,533,000Revenue
0.00Shares Out
58Employees

Margins

65.44%Gross
23.33%EBITDA
21.59%Operating
21.65%Pre-Tax
25.69%Net

Valuation

35.34P/E
5.81P/B
9.08EV/Sales
36.17EV/EBITDA
71.07P/FCF

Growth (CAGR)

14.40%Rev 3Yr
10.95%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

14.38%ROA
17.92%ROE
12.19%ROIC

Financial Health

¥825,731,000Cash & Cash Equivalents
¥-494,700,000Net Debt
21.86%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Immuno-Biological Laboratories Co., Ltd. (ticker: 4570) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 58 employees. Market cap is $8.8B.

The current price is 945 with a P/E ratio of 35.34x and P/B of 5.81x.

ROE is 17.92% and operating margin is 21.59%. Annual revenue is $970M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Immuno-Biological Laboratories Co., Ltd. (4570) Stock Forecast 2026 ¥945 — Price, Financials & Analyst Targets | Alpha Lenz